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Abstract
Background: Depression is associated with immunological responses as reflected by altered levels of circulating
cytokines. Alcohol use and trauma may modulate immune activity, and few studies have investigated these factors
in depressed patients. We aimed to explore the association between circulating peripheral cytokine levels and
degree of depressive symptoms, taking trauma and alcohol into account.
Methods: The study was a cross-sectional assessment of patients at admission to a specialized psychiatric center in
Norway. A total of 128 patients were included. Information was gathered using the self-administered questionnaires
Beck Depression Inventory-II (BDI-II) and the Alcohol Use Disorders Identification Test (AUDIT), in addition to clinical
interviews recording childhood or adult life trauma. Serum levels of the cytokines Interleukin-1β (IL-1β), Interleukin-1
Receptor Antagonist (IL-1RA), Tumor Necrosis Factor-α (TNF-α) and the chemokine Monocyte Chemoattractant
Protein-1 (MCP-1) were assessed. A Luminex bead-based multiplex assay was used for cytokine measurements.
Patient cytokine levels were compared to those of healthy volunteers by the Mann-Whitney U test.
Results: Levels of cytokines did not differ across patients with mild, moderate and severe depression. AUDIT score
was not related to cytokine levels, but to level of depression. A history of trauma was related to higher levels of IL-
1RA and TNF-α (p = 0.048 and p = 0.033, respectively), especially among the severely depressed. Serum levels of
MCP-1 and TNF-α were significantly higher among psychiatric patients than in healthy volunteers.
Conclusions: Findings indicate that depression was not related to levels of circulating cytokines among patients in
treatment, but that traumatized patients had higher levels of IL-1RA and TNF-α than patients without trauma experience.
The lack of relationship between cytokine level and depression was evident both in those without and with trauma.
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Background
Patients with major depressive disorder (MDD) are found
to have significantly elevated levels of circulating pro-
inflammatory cytokines, such as IL-6, TNF-α and IL-1RA
[1–3]. There is also some evidence showing that recovery
from depressive disorder correlates with return of the in-
flammatory state to normality [4]. A relationship between
immune responses and depression is illustrated by the fact
that up to 50% of patients develop clinical depression
following high doses of immune therapy with interferon-α
(IFN-α) [5]. Also, there is some evidence that elevated
cytokine levels may predict depressive illness, suggesting a
causal relationship between elevated immune activation
and MDD [6, 7].
In addition to MDD, pro-inflammatory cytokines have been
found to accompany anxiety disorders such as general anxiety
disorder [8, 9], panic disorder and the spectrum of phobias
[10] in addition to post-traumatic stress disorder (PTSD)
[11]. This may be due to activation of central and peripheral
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immune cells releasing cytokines, as well as activation of the
stress response system of the hypothalamic-pituitary-adrenal
(HPA) axis by pro-inflammatory cytokines [12].
One possible confounder for the relationship between
cytokines and mental health disorders might be the use of
anti-inflammatory drugs, where non-users have higher
levels of IL-1β, IL-6, and TNF-α [11]. Other factors that
might cause variations are sample characteristics like co-
morbidity, type of trauma experienced, and time elapsed
since the trauma [10, 13]. Such inconsistencies also apply
to eating disorders, where previous results are conflicting
[14, 15]. This suggests that the relationship between im-
munological functioning and the broad spectrum of psy-
chiatric disorders should be further examined.
Alcohol use disorder is comorbid in about 30% of pa-
tients with major depression, which makes it important to
consider alcohol use in investigations of immune changes
in depression [16]. Although acute alcohol consumption
inhibits immune response, resulting in suppression of the
pro-inflammatory cytokines, chronic alcohol use is associ-
ated with increased pro-inflammatory cytokine production
due to sensitization of immune cells [17, 18]. The result-
ing dysregulation of the innate immune system may lead
to the development of depression [19], and the response
may lead to development and progression of depressive
disorders among alcoholics [20]. Assessing alcohol de-
pendence to evaluate immune changes in depression pa-
tients is therefore critical [21].
Elucidating the role of inflammation in depressed pa-
tients in light of previous alcohol use and traumatic life
events might provide further insight into the mechanisms
of how depressive disorders develop. This could have im-
portant translational and clinical implications, such as the
development of new therapeutic agents which target the
immune system in treatment of major depression. Im-
munological biomarkers could be used to identify the kind
of treatment an individual is likely to benefit from. We
aimed to explore the association between circulating per-
ipheral cytokine levels and degree of depressive symp-
toms, taking trauma and alcohol into account.
Methods
Study participants and recruitment procedure
Patients were recruited at admission to Modum Bad, a
specialized psychiatric center in Norway. The facility
treats patients with long- standing and treatment-resistant
trauma, anxiety, eating and depression disorders. Patients
with severe self-destructive behavior or psychotic disor-
ders were not eligible for admission. The center does not
treat patients with substance abuse disorders (SUD) as
such, but many patients have comorbid addiction as part
of their problem spectrum. The facility offers group and
individual therapies in a 12-week inpatient treatment pro-
gram. Therapy is paid by public insurance, and patients in
work are entitled to sick leave while in treatment. The
staff is multidisciplinary, including psychiatrists, psycholo-
gists, nurses, art therapists, occupational therapists, social
workers and pastoral staff. Data were collected from
March 2015 to April 2016. The study was approved by the
Norwegian Regional Ethics Committee (REK) prior to
data collection (reference number 2014/2189).
Patients were recruited from the following units:
Depression, Eating Disorders, Anxiety and Trauma. The
patients joined the study in groups of eight at a time.
They were given a 15-min presentation about the study
during group therapy by the first author on one of the
first days of their stay. A written brochure was handed
out, explaining the aim of the study and the procedures
involved. A written consent form was also distributed to
each potential participant. Altogether, 148 (59% of the
249 patients approached) gave their written consent, and
one individual withdrew her consent two weeks later.
We excluded 19 patients from the data set, due to
extreme cytokine levels indicating acute infections.
Thus, the present study included baseline data provided
by 92 women (72%, mean age 39.04, SD 11.26) and 36
men (28%, mean age 49.06, SD 9.36), giving a total of
128 patients. The 102 patients who did not participate
consisted of 82 women (80%, mean age 35.77, SD 11.83)
and 21 men (21%, mean age 44.52, SD 8.58).
Healthy volunteers group
As a control group, we utilized data from an experimental
study with healthy volunteers performed by our group [22].
Sampling procedures are detailed in the original study. In
short, healthy volunteers were recruited through an adver-
tisement in the Correctional Service Staff Academy in Oslo,
Norway. The volunteers were 20 males aged from 20 to 45
(mean age 28.84, SD 5.3) who all had previous experience
of high-dose alcohol drinking. Exclusion criteria were hav-
ing any significant medical illness, alcohol or other sub-
stance use disorders, or metabolic disorders. Demographic
information was recorded, the AUDIT questionnaire was
answered, and cytokines were analyzed by venous blood
collection. The blood was collected at 7 am following an
overnight fasting. One volunteer was excluded due to an
extreme blood level of TNF-α. For the experimental study,
an inclusion criterion was some experience of high-dose al-
cohol drinking but current non-dependence on alcohol.
Thus, an inclusion maximum was set to 15 on the AUDIT.
As this volunteer group differed in age and gender from the
patients in our clinical study, we selected the youngest male
patients from our study to be compared to this healthy vol-
unteer sample with regard to cytokine levels.
Methods
All patients were interviewed by trained psychologists or
psychiatrists using the Mini-International Neuropsychiatric
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Interview (MINI) [23]. The measurements were conducted
during the first week of admission. The MINI interview re-
sults in a diagnosis in the 10th revision of the International
Classification of Diseases and Related Health Problems
(ICD-10). A combination of psychometric questionnaires
and clinical judgment was also taken into account in asses-
sing disorders. There were 54 patients with only one dis-
order, and 59 with two or more disorders. There were 15
patients with missing diagnosis and 14 with missing trauma
status due to staff failing to record the patient’s disorder.
Disorders within F30–39 were treated as one variable of
mood disorders. Disorders within the range of F40–49 were
merged to one variable of anxiety disorders. Disorders
within F50.0-F50.9 were merged to one variable of eating
disorders.
In addition, the patients completed various self-report
questionnaires on a computer or digital tablet. The fol-
lowing questionnaires were included:
The 21-item Beck Depression Inventory (BDI-II). The
BDI-II [24] was administered by the therapists to assess
the level of depressive symptoms during the two weeks
prior to the interview. The Norwegian validated version
was used [25, 26]. Each of the 21 items is scored from 0 to
3. Based on the average score, we categorized the answers
into three levels of depression severity: Minimal and mild
depression (score 0–18), moderate (score 19–29), and se-
vere (score 30–63).
The Alcohol Use Disorder Identification Test (AUDIT).
This is a 10-item screening test designed to identify harm-
ful, hazardous or possible alcohol dependence the last
12 months. The AUDIT has been proven able to detect
DSM-IV alcohol dependence and DSM-IV alcohol use dis-
order (AUD) when compared with semi-structured clin-
ical interviews [27]. Some examples of questions are:
“How often do you have a drink containing alcohol?” and
“How many drinks containing alcohol do you have on a
typical day when you are drinking?” The scores range
from 0 to 4. In these examples, a score of 0 refers to
“never” and “1–2 drinks”, respectively. A higher score re-
fers to a more severe drinking pattern, and in these two
examples, a score of 4 means “4 times a week” and “10 or
more drinks”. The cutoff scores for harmful or hazardous
drinking were set at 8 for men and 6 for women [28].
Trauma history was recorded by therapists at the facil-
ity as part of clinical history taking. There were five
questions on trauma exposure: 1) Has the patient been
exposed to sexual assaults in childhood? 2) Has the pa-
tient been exposed to physical abuse in childhood? 3)
Has the patient during childhood experienced other
traumatic events which have led to serious problems
later in life? 4) Has the patient been exposed to sexual
assaults or abuse in adulthood (after 18 years of age)? 5)
Has the patient in adulthood experienced other trau-
matic events which led to serious problems later?
Blood collection and serum preparation
The blood samples were taken in the laboratory at Modum
Bad between 8 and 9 am. One of the groups from the De-
pression Unit had their blood samples taken between 12
and 3 pm. The blood samples were collected in Vacuette
8 ml serum tubes, which were immediately turned upside
down about 8–10 times. They were then set to rest in a
blood tube stand for between 30 min and one hour before
being centrifuged in a Kubota 2420 swing-out centrifuge at
room temperature. The centrifuging procedure was set to
10 min, and the centrifuge achieved a rotation power of
1917 g. The separated serum was drawn from the Vacuette
tubes with a 1 ml single use pipette into two 2 ml Nunc
tubes. The samples were then stored in a − 80 degrees
Celsius freezer until assay.
Cytokine measurements
All samples were thawed on ice, vortexed, and then spun
down a tube with 250 μl serum at 14,000×g for 10 min
at 4 °C, before dilution (1 + 4) and further processing.
The following cytokines were assessed: IL-1β, IL-1RA,
IL-6, IL-10, IL-17A, IFN-y, MCP-1 and TNF-α. These
cytokines were selected based on the available literature
on the neuroimmune correlates of psychiatric disorders.
We present cytokines that were within the detectable
range, which were IL-1β, IL-1RA, MCP-1 and TNF-α.
Cytokine measurements were performed using Bio-Plex
xMAP technology (Bio-Rad, Austin, Texas, USA) with a
Luminex IS 100 instrument (Bio-Rad, Hercules, Califor-
nia, USA), powered using Bio-Plex Manager (version 6.0.
1) software. Multiplex bead-based technologies such as
Luminex allow detection and quantification of multiple
cytokines with good efficiency, speed and dynamic range
at reasonable cost. The assay was performed according
to the manufacturer’s instructions, but an additional
standard point was included. To achieve a more reliable
result, individual sets of samples from patients were run
in the same assay, all samples were assayed in duplicate
and a magnetic plate washer was used during assay set
up. The StatLIA software package (version 3.2, Brendan
Scientific, Carlsbad, California, USA), incorporating a
weighted, five-parameter logistic curve-fitting method,
was used to calculate sample cytokine concentrations.
Longitudinal controls were used in order to validate
inter-assay variation: IL-1β (18.1), IL-1RA (10.2), MCP-1
(6.7) and TNF-α (7.4). Numbers in parentheses are
inter-assay coefficients of variability (CV), where a lower
number is better. Any number below 21 is considered
acceptable. The mean inter-assay CV for all blood sam-
ple plates was 10.4%. The serum levels were measured in
picograms per milliliter (pg/ml). The minimum detect-
able values were 0.01 pg/ml for IL-1β, 3 pg/ml for IL-
1RA, 0.76 pg/ml for MCP-1, and 0.02 pg/ml for TNF-α.
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Statistical analysis
The statistical package SPSS version 23 for Windows (SPSS
Inc., Chicago IL, USA) was used for the statistical analysis.
One patient failed to fill out the AUDIT questionnaire, and
was treated as missing and excluded from the analysis. De-
scriptive statistics were used to present the cytokine values.
The values were rather skewed, and therefore presented by
medians and 25/75 percentiles. We attempted to normalize
the skewed cytokine data by log transformation. However,
the Kolmogorov-Smirnov test of normality remained sig-
nificant, and we therefore did not explore this approach
further. Nonetheless, we explored the analyses with and
without log-transformed data, which remained unchanged.
Undetectable cytokine levels were imputed with 1% of the
mean value. In the patients, 64 (50.39%) imputations of the
cytokine IL-1β were conducted, 1 (0.9%) of IL-1RA, 9 (7.
09%) of MCP-1, and 53 (41.73% of TNF-α. In the healthy
volunteers, 6 (31.6%) imputations of IL-1β were conducted,
none of IL-1RA, 5 (26.3%) of MCP-1, and 15 (79%) of
TNF-α. These undetectable cytokine levels were above
zero, but under the detectable limit, leaving imputation as a
way of presenting undetectable levels in close resemblance
to their actual levels. Patients with cytokine levels above the
95th percentile were defined as outliers, and removed from
the material, thus reducing the potential distortion from
any somatic inflammatory diseases. For the continuous
variable of age, Spearman’s rho correlation coefficient was
used. The significance level between the cytokines and cat-
egorical variables was calculated by the Mann-Whitney U-
test and by the Kruskal-Wallis one-way ANOVA. Pearson’s
chi-square was used for calculating the significance level
between the categorical variables. Finally, a comparison of
mean cytokine values between patients and healthy volun-
teers was made. Group differences in the levels of cytokines
between the patients and healthy volunteers were calcu-
lated using the Mann-Whitney U test, and p-values for the
tests are reported. All tests were two-tailed with statistical
significance set at the 5% level. Some of the group-wise
comparisons may have lacked statistical power due to small
group sizes, raising the possibility of type II error.
Results
Table 1 presents demography, medication, trauma history,
and diagnosis across the BDI-II scores categorized into
three different levels. The only difference between these
three levels of depression was the AUDIT scores, where the
higher score was in those with moderate depression (p = 0.
009). The use of anti-inflammatory and anti-depressive
medication was positively associated with depression sever-
ity. A positive history of trauma was most frequent in the
severely depressed patients. Patients classified under the
main diagnostic groups (mood/anxiety/eating/trauma) had
a uniform distribution of depression severity.
Table 2 shows the distribution of cytokine values ac-
cording to demography, distress, medication, trauma
and diagnostic groups. Levels of IL-1β were significantly
higher in the group with mood disorder and anxiety dis-
order than in those without (p = 0.037 and p = 0.008, re-
spectively). IL-1RA and TNF-α were significantly higher
in patients with a history of trauma than in those with-
out trauma experience (p = 0.048 and p = 0.033, respect-
ively). Participants scoring above cutoff in the AUDIT
had higher values of all measured cytokines; however,
the differences were not statistically significant.
Table 3 displays mean cytokine values from the 19
male, healthy volunteers and 19 matched patients from
our clinical study. All levels were higher in the patient
group than in the healthy volunteers, with MCP-1 and
TNF-α reaching statistical significance (p = 0.012 and
p < 0.001, respectively). The selected patient group was
older than the healthy volunteers group (p < 0.001). We
also performed analyses of a patient cohort consisting of
all patients compared to the healthy volunteers, and of
all 36 male patients compared to the healthy volunteers.
However, these different approaches did not change the
results significantly, the findings being consistent across
male and female patients, as well as between the whole
sample and the healthy volunteers sample.
To investigate possible effects of trauma history or alco-
hol use on the relationship between cytokine levels and
level of depression as quantified by the BDI-II, we strati-
fied the material into non-traumatized and traumatized
patients (Fig. 1) and those scoring below or above clinical
cutoff on AUDIT (Fig. 2). As depicted in Fig. 1, patients
who were categorized in the minimal or mild depression
group, as well as in the severe depression group, had sig-
nificantly different levels of cytokine IL-1RA when strati-
fied on trauma and no trauma experience (p = 0.046 and
p = 0.047, respectively). This was also true for levels of
TNF-α with the same strata in the severe depression
group (p = 0.029). There were no significant relationships
between cytokine levels and depression levels in the two
strata of patients below and above AUDIT score.
Discussion
Patients with mood disorder and anxiety disorder had
higher levels of IL-1β, but we found no systematic relation-
ship between level of depression and level of the measured
cytokines. Patients reporting trauma had higher levels of
the cytokines IL-1RA and TNF-α. We found no significant
relationship between cytokines and AUDIT scores.
The observed lack of relationship between cytokine
levels and level of depression may be because patients at
this high-threshold facility all have increased levels of cy-
tokines at admission. They represent a treatment-
resistant population that has suffered for years with
mental illness and received mental health treatment with
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no or little effect. A consequence may be that the im-
mune system is chronically activated. However, despite
not reaching statistical significance, mean and median
cytokine levels were generally higher in groups who
scored high on depression. The use of both antidepres-
sants and anti-inflammatory drugs has been reported to
distort the immune response, which may have contrib-
uted to the non-significant findings [29].
We found a relationship between patients suffering
childhood or adulthood trauma and higher cytokine
levels, represented by IL-1RA and TNF-α being signifi-
cantly elevated, but we found no links between child-
hood trauma or adulthood trauma and depression level.
This led us to perform a stratified analysis investigating
non-traumatized and traumatized patients separately. In
these strata, we found a difference in levels of IL-1RA in
the minimal to mild depression group, and in levels of
IL-1RA and TNF-α in the severe depression group.
Stress-induced depression may follow inhibited gluco-
corticoid release as a result of a chronically activated
HPA axis, a sign of inflammation [30]. In traumatized or
maltreated children, insufficient glucocorticoid signaling
may potentially lead to an unrestrained state of inflam-
mation as adults, rendering them vulnerable to depres-
sion [31]. Studies report that childhood maltreatment is
a predictor of elevated levels of inflammatory markers in
adulthood, and such individuals are more susceptible to
developing depression [32]. Also, adult experiences of
trauma may lead to the development of chronic stress
and thus elevated pro-inflammatory cytokines [33].
The elevated IL-1RA level in the traumatized patients may
be a result of the initial inflammatory response being coun-
tered by a down-regulated inflammatory response [34, 35],
limiting the pro-inflammatory effects of IL-1 [36]. Previous
studies found elevated levels of IL-1β [11, 37, 38] and TNF-α
[11, 39], while others found no such association of IL-1β
[39], TNF-α [40] or other neuroimmune biomarkers. One
possible explanation for these mixed results may be that
different kinds of trauma yield different immunologic re-
sponses. For instance, whether the trauma was experienced
as a child or as an adult is a relevant factor [13]. The HPA
axis and brain in childhood are immature and developing,
and the adaptive response to maltreatment has long-lasting
effects on the stress response system. As a consequence,
some individuals develop a persistent vulnerability to
stressors. This maladaptive vulnerability accompanies them
in adult life, potentially making such individuals more suscep-
tible to developing depression or anxiety disorders [41, 42].
Score above cutoff on the AUDIT questionnaire, possibly
indicating alcohol use problems, was related to level of
Table 1 Clinical characteristics of the included patients according to level of depression. Depression severity was measured by the
Beck Depression Inventory-II (BDI-II)
Variable Minimal or mild
depressiona
Moderate
depression
Severe depression
n = 28 (21.9%) % / SD n = 42 (32.8%) % / SD n = 58 (45.3%) % / SD Sig.b
Demography
Women n (%) 20 71.4 28 66.7 44 75.9 0.600
Age (years) Mean (SD) 39.4 10.8 44.2 12.0 41.3 11.7 0.210
Alcohol use
AUDIT scorec Mean (SD) 4.70 4.1 6.7 5.4 3.7 4.3 0.009d
Medication
Anti-inflammatory drug (any) n (%) 5 17.9 5 11.9 9 15.5 0.775
Antidepressants (any) n (%) 9 32.1 12 28.6 22 37.9 0.609
History of trauma
Childhood trauma n (%) 15 62.5 23 62.2 25 48.1 0.316
Adult trauma n (%) 16 66.7 16 43.2 28 53.8 0.199
Any trauma n (%) 19 79.2 26 70.3 39 73.6 0.743
Main diagnosise
Mood disorder n (%) 8 34.8 14 36.8 10 19.2 0.139
Anxiety disorder n (%) 12 52.2 17 44.7 26 50 0.825
Eating disorder n (%) 3 13.6 5 13.2 14 26.9 0.181
MDD (ICD-10, F33)f n (%) 3 10.7 5 11.9 3 5.2 0.447
Notes: a14 of these patients scored 13 or less in the BDI-II, indicating that they were not depressed, and were classified with minimal depression. bSignificance for
categorical variables was tested with Pearson’s chi-square test, and for continuous variables with Kruskal-Wallis one-way ANOVA. cAUDIT: Alcohol Use Disorder
Identification Test. dAUDIT score was different across the levels of BDI-II. eMain diagnosis: Mood disorders: F30-F34, Anxiety disorders: F40-F44, Eating disorders:
F50.0-F50.3. fMDD: Major Depression Disorder, as classified by the ICD-10
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depression. However, we found no relationship between
levels of cytokines and AUDIT. This differed from our pre-
vious cross-sectional study in Nepal, where we found in-
creased pro-inflammatory cytokines in AUD (alcohol use
disorder) patients with comorbid MDD, but not with PTSD
[43, 44]. In line with the findings in that study, we investi-
gated whether there were different relationships between
cytokine levels and levels of depression in those with or
without an alcohol problem, but analyzing the data in this
way by stratifying according to AUDIT score did not reveal
any such effect in the present study. The literature suggests
that low levels of drinking might dampen an immuno-
logical response, while high levels may increase circulating
cytokines [18]. In the current study, patients scored quite
low on the AUDIT, indicating low levels of alcohol prob-
lems. This might explain the lack of relationship between
cytokines and AUDIT score.
When healthy volunteers were compared to a group of
matched patients, the patients were found to have higher
levels of the cytokines TNF-α and MCP-1. Although some
Table 2 Median levels (25th and 75th percentile) of peripheral circulating cytokines according to clinical characteristics of the
included patients
Variable IL-1β (pg/mL) IL-1RA (pg/mL) TNF-α (pg/mL) MCP-1 (pg/mL)
Median (25th,
75th percentile)
Sig.a Median (25th,
75th percentile)
Sig.a Median (25th,
75th percentile)
Sig.a Median (25th,
75th percentile)
Sig.a
Demography
Men n = 36 0.003 (0.003, 0.130) 0.604 26.2 (17.8, 46.1) 0.804 0.080 (0.046, 1.390) 0.346 27.7 (15.3, 43.7) 0.069
Women n = 91 0.030 (0.003, 0.160) 27.5 (17.4, 40.3) 0.420 (0.046, 2.450) 21.1 (11.5, 32.6)
Age 0.033 0.716 0.141 0.114 0.068 0.450 0.027 0.762
Psychometrics
AUDIT (under cutoff score) n = 95 0.003 (0.003, 0.160) 0.730 24.8 (16.5, 42.5) 0.342 0.420 (0.046, 1.930) 0.768 20.8 (11.4, 33.1) 0.497
AUDIT (over cutoff score) n = 32 0.050 (0.003, 0.128) 28.1 (20.5, 39.0) 0.420 (0.046, 2.393) 24.8 (10.4, 40.3)
BDI-2 (minimal and
mild depression)
n = 27 0.003 (0.003, 0.200) 0.840 24.0 (15.4, 41.1) 0.564 0.420 (0.046, 2.450) 0.973 23.7 (14.4, 40.4) 0.277
BDI-2 (moderate and
severe depression)
n = 100 0.025 (0.003, 0.130) 27.5 (17.5, 42.9) 0.245 (0.046, 2.108) 21.9 (12.4, 34.1)
Medication
Anti-inflammatory drugs (no) n = 108 0.003 (0.003, 0.130) 0.050b 27.5 (17.4, 42.8) 0.634 0.180 (0.046, 2.008) 0.818 22.9 (13.2, 34.3) 0.095
Anti-inflammatory
drugs (yes)
n = 19 0.090 (0.003, 0.300) 24.8 (17.5, 34.3) 1.020 (0.060, 3.410) 22.2 (10.7, 38.6)
Antidepressants (no) n = 85 0.040 (0.003, 0.160) 0.510 27.5 (17.0, 42.5) 0.654 0.420 (0.046, 2.455) 0.370 24.3 (14.8, 37.9) 0.126
Antidepressants (yes) n = 42 0.003 (0.003, 0.133) 26.7 (19.6, 41.0) 0.185 (0.046, 1.250) 19.3 (10.6, 33.1)
History of trauma
Childhood trauma (no) n = 50 0.003 (0.003, 0.123) 0.379 24.5 (16.3, 39.4) 0.215 0.090 (0.046, 1.060) 0.060 23.8 (14.7, 37.7) 0.576
Childhood trauma (yes) n = 62 0.012 (0.003, 0.218) 28.1 (19.9, 41.3) 0.920 (0.046, 3.068) 22.9 (10.4, 36.9)
Adult trauma (no) n = 53 0.003 (0.003, 0.100) 0.235 22.8 (17.0, 35.5) 0.097 0.310 (0.046, 2.095) 0.786 23.3 (13.4, 33.1) 0.438
Adult trauma (yes) n = 59 0.060 (0.003, 0.170) 28.3 (18.7, 42.3) 0.420 (0.046, 2.450) 24.9 (10.7, 43.0)
Any trauma (no) n = 30 0.003 (0.003, 0.100) 0.154 21.7 (14.8, 30.7) 0.048c 0.070 (0.046, 0.775) 0.033d 23.5 (16.9, 32.7) 0.838
Any trauma (yes) n = 83 0.040 (0.003, 0.190) 28.4 (18.7, 42.1) 0.920 (0.046, 2.900) 23.7 (10.6, 38.6)
Main diagnosise
Mood disorder (no) n = 80 0.060 (0.003, 0.200) 0.037f 27.1 (17.3, 41.7) 0.982 0.390 (0.046, 2.450) 0.634 22.8 (11.6, 38.4) 0.829
Mood disorder (yes) n = 32 0.003 (0.003, 0.060) 26.9 (20.4, 39.3) 0.310 (0.046, 2.045) 24.1 (14.1, 33.4)
Anxiety disorder (no) n = 55 0.003 (0.003, 0.090) 0.008g 25.5 (17.5, 37.6) 0.325 0.060 (0.046, 1.780) 0.111 23.8 (13.9, 33.1) 0.740
Anxiety disorder (yes) n = 57 0.090 (0.003, 0.270) 29.3 (18.7, 44.1) 0.920 (0.046, 3.340) 23.3 (10.0, 43.0)
Eating disorder (no) n = 91 0.003 (0.003, 0.160) 0.429 28.1 (18.7, 42.1) 0.171 0.420 (0.046, 2.460) 0.561 23.7 (13.2, 38.6) 0.414
Eating disorder (yes) n = 21 0.003 (0.003, 0.115) 22.3 (15.7, 36.0) 0.100 (0.046, 1.905) 22.2 (11.8, 31.3)
Notes: aSignificance levels for categorical variables were tested with the Mann-Whitney U test and for continuous variables with Spearman’s rho correlation.
bPatients using anti-inflammatory drugs had higher levels of IL-1β. Exact p-value: 0.0498. c + dPatients with trauma history had higher levels of IL-1RA and TNF-α.
eMain diagnosis: Mood disorders: F30-F34, Anxiety disorders: F40-F44, Eating disorders: F50.0-F50.3. fPatients with mood disorders had higher levels of IL-1β.
gPatients with anxiety disorders had higher levels of IL-1β
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Table 3 Mean age (SD) and mean levels (SD) of peripheral circulating cytokines in healthy volunteers and a subgroup of matched patients
Variable Matched patients Healthy volunteers Sig.a
n = 19 n = 19
Age (years) 42.5 (7.9) 28.8 (5.4) <0.001b
Il-1β (picograms/ml) 0.15 (0.31) 0.13 (0.19) 0.740
Il-1RA (picograms/ml) 36.3 (33.0) 35.4 (19.5) 0.385
TNF-α (picograms/ml) 2.67 (6.67) 0.82 (2.75) < 0.001c
MCP-1 (picograms/ml) 26.8 (21.4) 15.8 (15.5) 0.012d
Note: aSignificance levels were tested by the Mann-Whitney U test. bPatients were older than the healthy volunteers. c+d Levels of TNF-α and MCP-1 were higher in patients
Both healthy volunteers and matched patients were male
Fig. 1 Distribution of cytokine levels (mean, upper bound of 95% CI) in depression groups for non-traumatized vs. traumatized patients (any trauma; child-
hood or adult) grouped by the Beck Depression Inventory-II. An asterisk (*) denotes a significant difference between groups (Mann-Whitney U-test) (p < 0.05)
Toft et al. BMC Psychiatry  (2018) 18:95 Page 7 of 10
studies have found MCP-1 to be lower in patients with
MDD [45], our findings of higher levels of TNF-α and
MCP-1 in the patient group add to several studies show-
ing a correlation between psychiatric disorders and ele-
vated pro-inflammatory cytokines [46]. This general
heightened cytokine level among the patients could con-
tribute to masking differences in cytokines between differ-
ent levels of depression in the patients.
There are limitations to this study. The 19 healthy vol-
unteers were younger than the 19 youngest matched male
patients. Aging is associated with higher risk of comorbid-
ity, and these factors may result in increased levels of
TNF-α and IL-1 [47]. The healthy volunteers were male
only, which was unfortunate since the majority of the
patients were female. Unlike the healthy volunteers, the
patients were not fasting when the blood samples were
taken. Eating three meals a day versus one meal a day has
been shown to elevate levels of TNF-α and MCP-1, sug-
gesting eating habits could mediate inflammatory path-
ways [48]. The Body Mass Index (BMI) of the patients
was not assessed in this study. Studies have shown the
levels of pro-inflammatory cytokines to be higher in obese
people (BMI > 30 kg/m2). Adipocytes are known to re-
lease circulating cytokines, notably TNF-α, IL-1β and IL-6
[49], and one cannot exclude the possibility of BMI con-
founding the cytokine levels. Trauma history was recorded
during clinical interviews using five standardized ques-
tions regarding child and/or adult physical or sexual
Fig. 2 Distribution of cytokine levels (mean, upper bound of 95% CI) in depression groups for patients scoring below vs. above clinical cutoff for
AUDIT, grouped by Beck Depression Inventory-II
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abuse. These questions are less valid than validated
trauma questionnaires, but provide face validity since they
were discussed with each patient by trained staff. Further-
more, the study is cross-sectional and should be followed
by longitudinal studies. We decided to report the results
with uncorrected p-values. Using Bonferroni correction or
similar would be an overly conservative approach when
conducting multiple tests in an exploratory study. Conse-
quently, there is also a risk of type I errors. Against this
background, one should interpret the results with caution.
Despite these limitations, this study fills gaps in the litera-
ture by elucidating cytokine levels across trauma and de-
pression symptoms. Finally, there is a risk of type II errors
when analyzing such small samples.
Conclusions
Patients with a history of trauma had higher levels of the
cytokines IL-1RA and TNF-α. There were no associa-
tions between cytokine levels and depression severity,
even when analyzing in sub-groups stratified according
to variables that themselves were related to cytokine
level like trauma and alcohol use.
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